NYSE:EW - Edwards Lifesciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Edwards Lifesciences Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $230.55 +4.01 (+1.77 %) (As of 02/16/2020 04:00 PM ET) Add Today's Range$227.03Now: $230.55▼$230.7750-Day Range$219.86MA: $232.34▼$242.9952-Week Range$165.69Now: $230.55▼$247.64Volume679,679 shsAverage VolumeN/AMarket CapitalizationN/AP/E Ratio46.67Dividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves. Read More… Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryHealth Care Equipment SectorN/A Current SymbolNYSE:EW Previous Symbol CUSIP28176E10 CIK1099800 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E Ratio46.67 Forward P/E Ratio36.83 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees12,800 Outstanding SharesN/AMarket CapN/A Next Earnings Date4/28/2020 (Estimated) OptionableOptionable Receive EW News and Ratings via Email Sign-up to receive the latest news and ratings for EW and its competitors with MarketBeat's FREE daily newsletter. EW Rates by TradingView Edwards Lifesciences (NYSE:EW) Frequently Asked Questions What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." When did Edwards Lifesciences' stock split? How did Edwards Lifesciences' stock split work? Edwards Lifesciences's stock split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly issued shares were distributed to shareholders after the market closes on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corp (NYSE:EW) posted its earnings results on Thursday, January, 30th. The medical research company reported $1.46 earnings per share for the quarter, missing the consensus estimate of $1.49 by $0.03. The medical research company earned $1.17 billion during the quarter, compared to the consensus estimate of $1.15 billion. The business's revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.17 EPS. View Edwards Lifesciences' Earnings History. When is Edwards Lifesciences' next earnings date? Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 28th 2020. View Earnings Estimates for Edwards Lifesciences. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $6.15-6.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.98. The company issued revenue guidance of $4.6-5.0 billion, compared to the consensus revenue estimate of $4.70 billion. What price target have analysts set for EW? 22 equities research analysts have issued 12 month price targets for Edwards Lifesciences' shares. Their forecasts range from $159.00 to $300.00. On average, they anticipate Edwards Lifesciences' share price to reach $250.38 in the next year. This suggests a possible upside of 8.6% from the stock's current price. View Analyst Price Targets for Edwards Lifesciences. What is the consensus analysts' recommendation for Edwards Lifesciences? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 3 sell ratings, 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Edwards Lifesciences. What are Wall Street analysts saying about Edwards Lifesciences stock? Here are some recent quotes from research analysts about Edwards Lifesciences stock: 1. According to Zacks Investment Research, "Edwards Lifesciences exited the fourth quarter of 2019 on a mixed note with lower-than-expected earnings and a revenue beat. Globally, TAVR procedures increased on strong therapy adoption across all geographies. We are also upbeat about strong sales growth within the Critical Care segment, driven by robust demand for the HemoSphere advance monitoring platform and continued adoption of Smart Recovery. The company continued benefiting from its CASMED acquisition. Moreover, a lifted 2020 EPS guidance raises investors’ optimism on the stock. In the past year, shares of Edwards Lifesciences have outperformed the industry. Meanwhile, dismal performances within Surgical Structural Heart and TMTT segments raise concern. Also, escalating costs put pressure on the margins in the fourth quarter." (2/3/2020) 2. BTIG Research analysts commented, "As we cautioned in our Q1 preview, TAVR results missed Street estimates. While we have no doubt that the underlying market remains strong, results have been light for 4+ quarters now, making us question if the market growth is a tad less than expected or if share is slightly shifting. Even so, management maintained an upbeat tone and there was no change to TAVR guidance but with Boston Scientific’s (BSX, Lotus approved in the U.S. tonight, we have to think that combined with weak Q1 results, shares may see pressure. On longer-term drivers, mitral sales were $4M in Q1 and although early feedback on PASCAL has fostered management’s own confidence in its outlook, we feel hitting $40M in revenue this year is a lofty goal. On the positive side, we would point to management’s bullishness on the revenue ramp in 2H and the solid expense control driving the EPS beat." (4/24/2019) Has Edwards Lifesciences been receiving favorable news coverage? Press coverage about EW stock has been trending neutral this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Edwards Lifesciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Edwards Lifesciences. Are investors shorting Edwards Lifesciences? Edwards Lifesciences saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,350,000 shares, an increase of 18.7% from the December 31st total of 1,980,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.1% of the shares of the company are short sold. View Edwards Lifesciences' Current Options Chain. Who are some of Edwards Lifesciences' key competitors? Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII). What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Walt Disney (DIS), Home Depot (HD), Visa (V), Mastercard (MA), Gilead Sciences (GILD), QUALCOMM (QCOM) and UnitedHealth Group (UNH). Who are Edwards Lifesciences' key executives? Edwards Lifesciences' management team includes the folowing people: Mr. Michael A. Mussallem, Chairman & CEO (Age 66)Mr. Scott B. Ullem, Corp. VP & CFO (Age 52)Mr. Donald E. Bobo Jr., Corp. VP of Strategy & Corp. Devel. (Age 57)Mr. Robert W. A. Sellers, Principal Accounting Officer, VP & Corp. ControllerDr. Todd J. Brinton, Corp. VP of Advanced Technology & Chief Scientific Officer Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (4.28%), FMR LLC (3.88%), Bank of New York Mellon Corp (2.97%), Sands Capital Management LLC (2.91%), Jennison Associates LLC (2.35%) and Massachusetts Financial Services Co. MA (0.77%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences. Which major investors are selling Edwards Lifesciences stock? EW stock was sold by a variety of institutional investors in the last quarter, including Sands Capital Management LLC, Jennison Associates LLC, Thrivent Financial for Lutherans, Marshall Wace North America L.P., Bank of New York Mellon Corp, Bessemer Group Inc., Partner Fund Management L.P. and Wedgewood Partners Inc.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences. Which major investors are buying Edwards Lifesciences stock? EW stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., Amundi Pioneer Asset Management Inc., Prudential Financial Inc., William Blair Investment Management LLC, Captrust Financial Advisors, Skandinaviska Enskilda Banken AB publ and First Republic Investment Management Inc.. View Insider Buying and Selling for Edwards Lifesciences. How do I buy shares of Edwards Lifesciences? Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $230.55. MarketBeat Community Rating for Edwards Lifesciences (NYSE EW)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 1,151 (Vote Outperform)Underperform Votes: 812 (Vote Underperform)Total Votes: 1,963MarketBeat's community ratings are surveys of what our community members think about Edwards Lifesciences and other stocks. Vote "Outperform" if you believe EW will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EW will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: What does RSI mean?
